Market cap
₹14 Cr
Revenue (TTM)
₹70 Cr
P/E Ratio
9
P/B Ratio
0.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 30.53 | 11.79 | 13.85 |
| EBIT | -- | -- | 35.13 | 10.84 | 23.02 |
| Net Profit | -- | -- | 56.10 | 15.03 | 17.16 |
| EPS | -- | -- | 56.10 | 3.58 | -41.02 |
| Book Value | -- | -- | 10.30 | 35.39 | -9.79 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| 5.40 | 5.03 | 5.15 | 4.98 | 6.06 |
| Net Margin
| 2.12 | 2.10 | 2.30 | 1.92 | 2.15 |
| Return on equity
| 8.51 | 18.95 | 9.79 | 6.82 | 8.90 |
| Return on Capital
| 13.52 | 19.28 | 13.10 | 12.56 | 14.91 |
| Return on Assets
| 3.59 | 5.23 | 3.97 | 3.13 | 3.67 |
| Debt to Equity (x)
| -- | -- | 0.83 | 0.60 | 0.39 |
Profitability
ROCE
13.10
Higher than Peers by 12.25
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
13.10
|
12.56
|
14.91
|
22.10
|
33.73
|
|
Peer Median
|
0.85
|
9.15
|
9.86
|
10.38
|
--
|
ROE
9.79
Higher than Peers by 8.95
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
9.79
|
6.82
|
8.90
|
23.28
|
45.95
|
|
Peer Median
|
0.85
|
5.99
|
5.33
|
7.17
|
--
|
ROA
3.97
Higher than Peers by 3.21
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
3.97
|
3.13
|
3.67
|
5.76
|
9.61
|
|
Peer Median
|
0.76
|
3.67
|
4.83
|
5.33
|
--
|
EBIT Margin
5.15
Higher than Peers by 7.08
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
5.15
|
4.98
|
6.06
|
5.29
|
3.70
|
|
Peer Median
|
-1.93
|
1.57
|
-0.69
|
-7.53
|
--
|
Net Margin
2.30
Higher than Peers by 0.55
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
2.30
|
1.92
|
2.15
|
2.11
|
2.04
|
|
Peer Median
|
1.75
|
7.26
|
3.51
|
5.34
|
--
|
Cash Profit Margin
2.46
Higher than Peers by 2.46
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
2.46
|
2.14
|
2.39
|
2.25
|
2.13
|
|
Peer Median
|
0.00
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
30.53
Lower than Peers by 3.40
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
30.53
|
32.11
|
-18.97
|
-9.78
|
51.75
|
|
Peer Median
|
33.93
|
59.03
|
23.78
|
185.48
|
--
|
EBIT Growth
35.13
Higher than Peers by 31.87
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
35.13
|
8.52
|
-7.14
|
28.98
|
60.42
|
|
Peer Median
|
3.27
|
0.71
|
-39.89
|
5.86
|
--
|
Net Profit Growth
56.10
Higher than Peers by 17.40
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
56.10
|
17.75
|
-17.19
|
-6.97
|
55.90
|
|
Peer Median
|
38.70
|
2.24
|
-1.56
|
-29.54
|
--
|
EPS Growth
56.10
Higher than Peers by 40.54
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
56.10
|
17.75
|
-39.53
|
-6.98
|
-93.10
|
|
Peer Median
|
15.56
|
15.99
|
20.00
|
-25.00
|
--
|
Book Value Growth
10.30
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
10.30
|
7.06
|
187.84
|
26.34
|
330.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.83
Higher than Peers by 0.83
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
0.83
|
0.60
|
0.39
|
2.00
|
1.52
|
|
Peer Median
|
0.00
|
0.00
|
0.00
|
0.08
|
--
|
Short term debt to equity ratio
0.35
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
0.35
|
0.52
|
0.21
|
1.45
|
1.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.09
Lower than Peers by 0.65
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.09
|
1.21
|
1.89
|
1.20
|
1.54
|
|
Peer Median
|
1.73
|
1.97
|
2.54
|
2.22
|
--
|
Quick Ratio
1.04
Lower than Peers by 0.62
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.04
|
1.21
|
1.85
|
0.91
|
1.49
|
|
Peer Median
|
1.66
|
2.38
|
3.33
|
2.05
|
--
|
Interest Coverage
2.50
Lower than Peers by 3.32
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
2.50
|
2.03
|
1.83
|
2.13
|
2.97
|
|
Peer Median
|
5.82
|
8.07
|
18.49
|
8.15
|
--
|
Operating Efficiency
Debtors to sales
24.67
Higher than Peers by 2.14
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
24.67
|
49.47
|
39.93
|
22.13
|
25.13
|
|
Peer Median
|
22.53
|
19.70
|
17.80
|
21.35
|
--
|
Asset Turnover
1.73
Higher than Peers by 0.88
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.73
|
1.63
|
1.70
|
2.72
|
4.69
|
|
Peer Median
|
0.84
|
1.87
|
0.60
|
0.25
|
--
|
Receivable days
114.19
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
114.19
|
145.45
|
122.72
|
91.22
|
69.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
2.49
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
2.49
|
1.69
|
19.13
|
15.75
|
3.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
64.92
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
64.92
|
74.63
|
61.58
|
45.99
|
35.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
51.77
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
51.77
|
72.50
|
80.28
|
60.98
|
37.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
6.97
Lower than Peers by 27.69
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
6.97
|
14.68
|
16.07
|
--
|
--
|
|
Peer Median
|
34.66
|
25.87
|
30.13
|
23.66
|
--
|
Price / Book Value
0.65
Lower than Peers by 0.29
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
0.65
|
0.97
|
0.96
|
--
|
--
|
|
Peer Median
|
0.94
|
1.84
|
1.22
|
0.81
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.64
|
--
|
0.43
|
0.69
|
--
|
EV/EBITDA
6.61
Higher than Peers by 15.91
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
6.61
|
8.17
|
7.10
|
4.43
|
2.51
|
|
Peer Median
|
-9.30
|
-24.50
|
-39.62
|
-10.36
|
--
|
Market Cap
11
Lower than Peers by 137
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
11
|
15
|
14
|
--
|
--
|
|
Peer Median
|
148
|
160
|
199
|
362
|
--
|